BioSpring in­vests €100M+ in­to new oligonu­cleotide API fa­cil­i­ties in Ger­many

While the city of Of­fen­bach, Ger­many has been a his­tor­i­cal cen­ter of ma­chine-build­ing and leather­mak­ing, the Ger­man con­tract man­u­fac­tur­er BioSpring is look­ing to make it a ma­jor cen­ter for in­gre­di­ent man­u­fac­tur­ing.

BioSpring an­nounced that it has ac­quired an ad­di­tion­al 30,000 square me­ters (323,000 square feet) of land to add to its cam­pus in the city of Of­fen­bach, Ger­many. BioSpring plans to use the land to build three new “pro­duc­tion units” to com­mer­cial­ly man­u­fac­ture oligonu­cleotide-based ac­tive phar­ma­ceu­ti­cal in­gre­di­ents, which can be used in dif­fer­ent types of can­cer ther­a­pies and oth­er drug prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER